NewAmsterdam Pharma N.V. (NAMS) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Supernus Pharmaceuticals (SUPN) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 10.4% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with +36.0% for SUPN. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.49 billion vs $2.45 billion), about 1.0 times the size, while Supernus Pharmaceuticals is growing revenue faster (+8.6% vs -50.6%).
Supernus Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.4% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | SUPN |
|---|---|---|
| Share price | $21.26 | $42.14 |
| Market cap | $2.49B | $2.45B |
| 1-day change | -3.93% | -2.11% |
| YTD return | -36.92% | -13.38% |
| 1-year return | -31.29% | -10.44% |
| 5-year return | +126.05% | +35.98% |
| Forward P/E | — | 9.45 |
| EPS (TTM) | $-2.16 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $718.95M |
| Revenue growth (YoY) | -50.61% | +8.63% |
| Net income (latest FY) | $-203.82M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | -1002.90% | -8.66% |
| Net margin | -905.74% | -5.36% |
| 52-week high | $42.21 | $59.68 |
| 52-week low | $20.94 | $40.51 |
| Distance from 52-week high | -49.63% | -29.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +133.54% | +46.54% |
| Average volume | 1.35M | 766.52K |
| Shares outstanding | 116.90M | 58.22M |
| Employees | 100 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SUPN has outperformed NAMS by 20.9 percentage points over the past year.
- Supernus Pharmaceuticals is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Supernus Pharmaceuticals grew revenue faster in its latest fiscal year (+8.63% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
NAMS vs SUPN FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Supernus Pharmaceuticals?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.49B compared with $2.45B for Supernus Pharmaceuticals (SUPN).
Which stock has performed better over the past year, NAMS or SUPN?
SUPN returned -10.44% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.